Cardiology Clinical Trials

California Pacific CURRENTS: The online journal of CPMC Research Institute

Thoratec Corporation MOMENTUM 3, Multi-center Study of MagLev Technology in Patients Undergoing MCS Therapy With HeartMate 3™ IDE Clinical Study Protocol

Description: The objective of the study is to evaluate the safety and effectiveness of the HM3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure.


  • Brett Sheridan, MD, FACS

Eligibility Requirements

Subjects, 18 y/o and older, with NYHA Class III with dyspnea upon mild physical activity, or NYHA Class IV; LVEF ≤ 25%; and inotrope dependent OR CI < 2.2 L/min/m2, while not on inotropes


Active and open to enrollment


Douglas Raggett, RN, 415-600-3777